| Explore Biomarkers Associated With Prognosis of Recurrent and Metastatic CRC After Surgery by Multi-omics Methods (NCT05501353) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2022-07-22 |
| Perioperative Outcomes of Simultaneous Colorectal and Liver Resections (NCT05475041) | Fondazione Poliambulanza Istituto Ospedaliero | 2022-06-30 |
| Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer. (NCT05243862) | Treos Bio Limited | 2022-06-02 |
| Radioembolization in Elderly/ Fragile Patients With mCRC (NCT05092880) | UMC Utrecht | 2022-06-01 |
| Dynamics of MSI and Genomic Profile of Colorectal Cancer In the Course of Immune Checkpoint Inhibitor Therapy (NCT06414304) | OncoAtlas LLC | 2022-06-01 |
| Preoperative Systemic Therapy for Colorectal Cancer Peritoneal Metastases (NCT05353582) | Sun Yat-sen University | 2022-06-01 |
| Evaluation of Tumour Growth and Oncological Treatment in Patients With CRLM Using Zebra Fish Embryo Model (NCT05289076) | University Hospital, Linkoeping | 2022-05-17 |
| Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients. (NCT04564898) | Gruppo Oncologico del Nord-Ovest | 2022-01-25 |
| A Phase lb/ll, Open Label, Single Arm Study With Olinvacimab and Capecitabine in mCRC Patients (OLCAP) (NCT04751955) | Korean Cancer Study Group | 2022-01-01 |
| Ablation vs Resection of Colorectal Cancer Liver Metastases (NCT05129787) | Oslo University Hospital | 2021-12-16 |
| Evaluation of Treatment PERSOnalization Based on Its Therapeutic Monitoring in Patients With Metastatic Colorectal Cancer Treated With REgorafenib (NCT04874207) | Rennes University Hospital | 2021-10-22 |
| PRELUDE-1 (Prospective Evaluation of Radiotherapy-induced Biologic Effects in Colorectal Cancer Oligometastatic Patients with LUng-limited Disease: Evolution of Cancer Genetics and Regulatory Immune Cells) (NCT04854213) | National Cancer Institute, Naples | 2021-10-06 |
| Radiotherapy Combined With Tislelizumab and Irinotecan in MSS/pMMR Recurrence and Metastatic Colorectal Cancer (NCT05160727) | Zhejiang Cancer Hospital | 2021-10-01 |
| Local Consolidative Therapy in Colorectal Cancer (NCT05062720) | Fox Chase Cancer Center | 2021-07-29 |
| Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease (NCT04595266) | Grupo Espanol Multidisciplinario del Cancer Digestivo | 2021-06-29 |
| Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in PMMR/MSS CRLM Patients (NCT04940546) | Sun Yat-sen University | 2021-06-16 |
| The Effect of ePRO on Quality of Life and Prognosis of Patients With Unresectable Metastatic Colorectal Cancer (NCT04684095) | Harbin Medical University | 2021-05-26 |
| Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC. (NCT04730544) | GERCOR - Multidisciplinary Oncology Cooperative Group | 2021-05-21 |
| Severe Neutropenia After HIPEC Using Mitomycin-C (NCT05513183) | Gangnam Severance Hospital | 2021-05-20 |
| Registry Platform Colorectal Cancer (NCT04867525) | iOMEDICO AG | 2021-05-01 |
| Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate (NCT04262687) | Federation Francophone de Cancerologie Digestive | 2021-04-06 |
| Feasibility Study of a 4 Stage Bowel Obstruction Cancer Diet (NCT04898842) | Royal Surrey County Hospital NHS Foundation Trust | 2021-03-02 |
| Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC): (NCT04607668) | G1 Therapeutics, Inc. | 2021-01-06 |
| COLLISION XL: Unresectable Colorectal Liver Metastases (3-5cm): Stereotactic Body Radiotherapy vs. Microwave Ablation (NCT04081168) | Amsterdam UMC, location VUmc | 2020-12-15 |
| Effect of Age, Body Mass Index and Tumor Sidedness in Metastatic Colorectal Cancer (NCT04543019) | Assiut University | 2020-12-01 |
| TheraSphere® For Treatment of Metastases in Liver (NCT04517643) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2020-11-12 |
| Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer (NCT04108481) | University of Iowa | 2020-10-05 |
| Precision Medicine for Colorectal Cancer Liver Metastasis Guided by Multi-omics Data Under the Umbrella Theory (NCT04525807) | Fudan University | 2020-09-01 |
| A Phase I/II Study With BM7PE Immunotoxin in Colorectal Cancer Patients (NCT04550897) | Oslo University Hospital | 2020-08-31 |
| Efficacy of VIC Regimen in BRAF Mutant Metastatic Colorectal Cancer (NCT04790448) | Sun Yat-sen University | 2020-07-27 |
| Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer (NCT04245865) | Vejle Hospital | 2020-06-26 |
| A Pilot Study to Explore the Role of Gut Flora in Colorectal Cancer (NCT04148378) | ProgenaBiome | 2020-03-02 |
| LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615) (NCT04031872) | The Netherlands Cancer Institute | 2020-01-01 |
| Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. (NCT03983954) | NeoTX Therapeutics Ltd. | 2019-10-10 |
| The mCRC Patients With pMMR/MSS or dMMR/MSI-H Status Received Palliative Chemotherapy Efficacy and Survival (NCT04482608) | Sun Yat-sen University | 2019-09-01 |
| Plasma 5hmC Signatures as a Marker of Colorectal / Appendiceal Peritoneal Metastasis (NCT04157322) | University of Chicago | 2019-08-26 |
| Living Donor Liver Transplant for Unresectable Colorectal Liver Metastases (NCT05248581) | University of Rochester | 2019-08-16 |
| To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of YYB101 With Irinotecan, Patients Who Are Metastatic or Recurrent Colorectal Cancer Patients (NCT04368507) | CellabMED | 2019-08-09 |
| Regorafenib and PD-1 Antibody in Combination With Radiotherapy for pMMR/MSS Metastatic Colorectal Cancer (NCT04030260) | Sun Yat-sen University | 2019-07-19 |
| Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer (NCT03657641) | University of Southern California | 2019-06-21 |
| Study of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and Chemotherapy (NCT03982121) | Gustave Roussy, Cancer Campus, Grand Paris | 2019-06-04 |
| Anticancer Vigilance Of Cardiac Events (AVOCETTE) in Metastatic Colorectal Cancer (NCT03923036) | University Hospital, Caen | 2019-04-01 |
| Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer (NCT03800602) | Emory University | 2019-01-15 |
| Improving Outcome of Selected Patients With Non-resectable Hepatic Metastases From Colo-rectal Cancer With Liver Transplantation (NCT03803436) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 2019-01-02 |
| Irinotecan Drug-eluting Bead Liver Embolisation Registry (NCT03697044) | The Christie NHS Foundation Trust | 2019-01-01 |
| A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors (NCT03775850) | Evelo Biosciences, Inc. | 2018-12-19 |
| Sym004 Versus Futuximab or Modotuximab in Patients With mCRC (NCT03549338) | Symphogen A/S | 2018-11-29 |
| Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal (NCT03751176) | Grupo Espanol Multidisciplinario del Cancer Digestivo | 2018-11-08 |
| Quality of Life After Cytoreductive Surgery and Intraperitoneal Chemotherapy (NCT03503071) | Kyungpook National University Hospital | 2018-10-01 |
| QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine (NCT03563157) | ImmunityBio, Inc. | 2018-09-28 |
| Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer (NCT03647839) | Australasian Gastro-Intestinal Trials Group | 2018-09-06 |
| Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (NCT03470350) | The Netherlands Cancer Institute | 2018-08-24 |
| Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Network (NCT03164655) | UNICANCER | 2018-07-25 |
| Nab-Sirolimus in Combination With FOLFOX & BEV as 1st Line Therapy in Patients With Advanced or Metastatic Colorectal Cancer (NCT03439462) | Aadi Bioscience, Inc. | 2018-07-01 |
| A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer (NCT03597581) | Inspirna, Inc. | 2018-06-05 |
| OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer - (NCT03750175) | Karen-Lise Garm Spindler | 2018-06-01 |
| METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin (NCT03388190) | University Hospital, Akershus | 2018-05-29 |
| Living Donor Liver Transplantation With Two Stage Hepatectomy for Patients With Isolated, Irresectable Colorectal Liver Metastases (NCT03488953) | Jena University Hospital | 2018-04-10 |
| FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status (NCT03142516) | Grupo Espanol Multidisciplinario del Cancer Digestivo | 2017-10-31 |
| A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer (NCT03144804) | Massachusetts General Hospital | 2017-10-31 |
| Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer (NCT03251612) | Vejle Hospital | 2017-09-22 |
| HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies (NCT03213314) | University of Edinburgh | 2017-09-07 |
| The Effects of General Anesthetics on Lymphocytes in Patients Undergoing Colorectal Cancer Resection and Mechanism Involved (NCT03193710) | Guizhi Du | 2017-09-01 |
| Evaluation of the Safety and the Tolerability of Durvalumab Plus Tremelimumab Combined With FOLFOX in mCRC (NCT03202758) | Centre Georges Francois Leclerc | 2017-08-29 |
| Comprehensive Genomic Profiling of Colorectal Cancer Patients With Isolated Liver Metastases to Understand Response & Resistance to Cancer Therapy (NCT03364621) | University Health Network, Toronto | 2017-08-29 |
| Study of the Therapeutic Response and Survival of Patients with Metastatic Colorectal Cancer (stage IV) and Treated According to the Guidelines of a Chemosensitivity Test, Oncogramme® (ONCOGRAM) (NCT03133273) | University Hospital, Limoges | 2017-07-24 |
| The p53 Colorectal Cancer Trial (NCT03149679) | Haukeland University Hospital | 2017-05-09 |
| Assessing How Normal Variations in CT Scanning Affects Its Interpretation (NCT03038568) | Memorial Sloan Kettering Cancer Center | 2017-01-27 |
| Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE Trial (NCT04721301) | University Hospital Heidelberg | 2017-01-15 |
| CE-IOUS Impact on Surgical Strategy of Liver Tumours and Liver Metastases (NCT05261113) | University of Regensburg | 2017-01-01 |
| Evaluation of CTCs Combined With Tumor Marker Detection of Efficacy of Chemotherapy in mCRC (NCT02948985) | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 2017-01-01 |
| AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer (NCT02380443) | Mirror Biologics, Inc. | 2016-09-01 |
| Panitumumab Skin Toxicity Prevention Trial (NCT03167268) | Ospedale San Carlo Borromeo | 2016-08-03 |
| A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy (NCT02959151) | Shanghai GeneChem Co., Ltd. | 2016-07-01 |
| Development of an IDEAL Framework to Standardise Cytoreductive Surgery for Colorectal Peritoneal Metastases (NCT03733184) | University of Manchester | 2016-03-10 |
| Zinc Supplement in Regorafenib Treated mCRC Patient (NCT03898102) | Chang Gung Memorial Hospital | 2016-03-01 |
| Intraperitoneal and System Chemotherapy Versus XELOX as First-line Chemotherapy for mCRC (NCT03792269) | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 2016-01-01 |
| Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study (NCT02316496) | GERCOR - Multidisciplinary Oncology Cooperative Group | 2015-09-23 |
| Effectiveness Study of Resection of Primary Tumor in Stage IV Colorectal Cancer Patients (NCT02149784) | Sun Yat-sen University | 2015-09-01 |
| Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorectal Cancer (NCT03556956) | AB Science | 2015-07-01 |
| To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers (NCT02179970) | CCTU- Cancer Theme | 2015-06-01 |
| Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma（FACT） (NCT02390947) | Jiangsu HengRui Medicine Co., Ltd. | 2015-01-01 |
| Possible Association of Intestinal Helminths and Protozoa With Colorectal Cancer Pathogenesis (NCT03173001) | Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan | 2015-01-01 |
| Pilot Study to Assess the Safety and Pharmacokinetics of 70-150μm Drug Eluting Beads Loaded With Irinotecan (DEBIRI). (NCT02350400) | Singapore General Hospital | 2014-06-01 |
| Study to Evaluate Real-world Pharmacoeconomics of Panitumumab in Metastatic Colorectal Cancer Patients (NCT02139215) | PeriPharm | 2014-04-01 |
| Capecitabine Plus Aflibercept as Maintenance Therapy Following Capecitabine Plus Oxaliplatin Plus Aflibercept in Patients With Metastatic Colorectal Cancer (NCT02085005) | Sanofi | 2014-03-01 |
| The Jules Bordet Institute Molecular Profiling Program Feasibility Trial (NCT01932489) | Jules Bordet Institute | 2013-12-01 |
| Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient (NCT01955629) | Sanofi | 2013-12-01 |
| Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer (NCT01910610) | GERCOR - Multidisciplinary Oncology Cooperative Group | 2013-10-30 |
| A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan (NCT01882868) | Sanofi | 2013-07-01 |
| Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases (NCT01508000) | European Organisation for Research and Treatment of Cancer - EORTC | 2013-06-01 |
| FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer (NCT01721954) | Sirtex Medical | 2013-05-01 |
| Colorectal Cancer (CRC) Cetuximab Elderly Frail (NCT01522612) | European Organisation for Research and Treatment of Cancer - EORTC | 2013-04-01 |
| RAS Switch in Patients With Metastatic RAS Native Colorectal Tumors Treated With 1st Line FOLFIRI-Cetuximab (NCT01943786) | Sofia Perea, Director Clinical Trials Unit. | 2013-04-01 |
| Monocentric Prospective Pilot Study Evaluating the Value of Indocyanine Green (ICG, Indocyanine Green) During a Surgical Resection of Cancerous Lesions Peritoneal Colorectal Origin. (NCT01982227) | Centre Hospitalier Universitaire de Saint Etienne | 2013-03-01 |
| Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects (NCT01892527) | Armando Santoro, MD | 2013-03-01 |
| Chemotherapy Alone Versus Chemotherapy Plus Targeted Therapy as Adjuvant Therapy for Initially Unresectable Colorectal Cancer Liver Metastases (NCT06027775) | Fudan University | 2013-01-01 |
| Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases (NCT01646554) | European Organisation for Research and Treatment of Cancer - EORTC | 2012-12-01 |
| Maintenance Metronomic Chemotherapy for Metastatic Colorectal Carcinoma (NCT01668680) | HaEmek Medical Center, Israel | 2012-09-01 |
| Colorectal Cancer Metastatic (NCT01670721) | Sanofi | 2012-08-01 |